Story thread · 2 reports / 2 sources
Beacon says gene therapy succeeds in key trial of rare eye disease XLRP
endpts.com · 6h · first report
How the coverage leans
Across 2 sources · syndicated copies counted once
Beacon Therapeutics has succeeded in a genetic eye disease where large drugmakers including Johnson & Johnson and Biogen have failed. On Monday, Beacon said its gene therapy for X-linked retinitis pigmentosa (XLRP) passed a Phase ...
The coverage
- Syncona jumps 6% after Beacon gene therapy trial success
investing.com · 3h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.